Chronic hepatitis B in pregnant women: Current trends and approaches

Table 5 Cessation of nucleoside analogues treatment after delivery

APASL 2016[8]	EASL 2017[9]	AASLD 2018[10]
Cessation of NA therapy (at delivery or 4-12 wk after delivery) is recommended in females without ALT flares and without pre-existing advanced liver fibrosis/cirrhosis. Continuation of NA treatment after delivery may be necessary according to maternal liver disease status	If NA therapy is given as prophylaxis, i.e., only for the prevention of perinatal transmission, its duration is not well defined (stopping at delivery or within the first 3 mo after delivery)	HBV-infected pregnant women who are not on antiviral therapy as well as those who stop antiviral at or early after delivery should be monitored closely for up to 6 mo after delivery for hepatitis flares and seroconversion. Long-term follow-up should be continued to assess need for future therapy

APASL: Asia-Pacific Association Society for the Study of the Liver; EASL: European Association for the Study of the Liver; AASLD: American Association for the Study of Liver Diseases; NA: Nucleoside analogues; ALT: Alanine aminotransferase.